HC Wainwright Has Optimistic Outlook of ALDX Q1 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – HC Wainwright lifted their Q1 2026 earnings estimates for Aldeyra Therapeutics in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at $0.27 EPS, FY2026 earnings at ($0.15) EPS, FY2028 earnings at $0.79 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.04 EPS.

Separately, BTIG Research restated a “buy” rating and set a $9.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, November 10th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.50.

Aldeyra Therapeutics Trading Up 3.2%

Shares of NASDAQ ALDX opened at $4.80 on Friday. Aldeyra Therapeutics has a 12-month low of $1.14 and a 12-month high of $7.20. The company has a market cap of $288.86 million, a price-to-earnings ratio of -8.42 and a beta of 0.97. The stock’s 50 day simple moving average is $5.01 and its 200 day simple moving average is $5.17.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of hedge funds have recently made changes to their positions in ALDX. Vanguard Group Inc. grew its holdings in Aldeyra Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock worth $18,750,000 after buying an additional 90,276 shares in the last quarter. 683 Capital Management LLC raised its stake in Aldeyra Therapeutics by 86.6% during the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after acquiring an additional 710,000 shares in the last quarter. AQR Capital Management LLC boosted its position in Aldeyra Therapeutics by 275.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after acquiring an additional 1,081,257 shares during the period. Kennedy Capital Management LLC boosted its position in Aldeyra Therapeutics by 12.9% during the 4th quarter. Kennedy Capital Management LLC now owns 1,255,838 shares of the biotechnology company’s stock worth $6,505,000 after acquiring an additional 143,625 shares during the period. Finally, Geode Capital Management LLC boosted its position in Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after acquiring an additional 8,769 shares during the period. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics News Roundup

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply upgraded near‑term forecasts: Q4 2026 EPS was raised from $0.02 to $0.27 and FY2026 was lifted from ($0.35) to ($0.15), with a smaller raise for Q1 2026 (from ($0.15) to ($0.13)). Those changes suggest the analyst now sees a nearer path to breakeven/profitability, which can be a material positive for a small biotech. MarketBeat: ALDX analyst updates
• Neutral Sentiment: HC Wainwright published a FY2030 estimate of $1.04 EPS — a long‑dated projection that provides a favorable long-term view but is distant and dependent on product launches/market adoption, so it’s less likely to drive near‑term price action. MarketBeat: ALDX long-term estimate
• Negative Sentiment: HC Wainwright also trimmed several estimates: Q2 2026 slightly down (from ($0.15) to ($0.16)), Q3 2026 cut (from ($0.08) to ($0.13)), FY2027 lowered (from $0.11 to $0.08), and FY2028/FY2029 projections reduced (FY2028: $0.95 → $0.79; FY2029: $1.25 → $1.08). These downgrades temper enthusiasm by lowering peak earnings expectations and signal continued execution or commercial risk. MarketBeat: ALDX estimate cuts
• Neutral Sentiment: Short‑interest reports posted in early March show zero reported short shares (data appears anomalous/placeholder), so there’s no clear short‑squeeze signal from those filings. Treat the short‑interest data as not actionable until clarified. MarketBeat: ALDX short interest

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.